Innoviva, Inc. (INVA)

Compare

18.08

+0.01

+(0.06%)

At close: April 3 at 4:00:02 PM EDT

Victoria’s Secret, Bitdeer, and More Stocks See Activist Action

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

Barrons.com 13 days ago

AQN

IRON

INVA
+0.06%
WEX, Lamb Weston, and More Stocks See Action From Activist Investors

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

Barrons.com 20 days ago

LW

JANX

TRS
Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc. (Nasdaq: INVA) (collectively, "Innoviva"), Armata's

PR Newswire 22 days ago

INVA
+0.06%
ARMP
Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

BURLINGAME, Calif., March 05, 2025--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference in Miami, FL on T

Business Wire 29 days ago

INVA
+0.06%
Innoviva Full Year 2024 Earnings: EPS: US$0.37 (vs US$2.75 in FY 2023)

Innoviva ( NASDAQ:INVA ) Full Year 2024 Results Key Financial Results Revenue: US$358.7m (up 16% from FY 2023). Net...

Simply Wall St. last month

INVA
+0.06%
Innoviva: Q4 Earnings Snapshot

BURLINGAME, Calif. AP) — Innoviva Inc. INVA) on Wednesday reported net income of $20.3 million in its fourth quarter.

Associated Press Finance last month

INVA
+0.06%
Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif., February 26, 2025--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted select corporate progress and achievements.

Business Wire last month

INVA
+0.06%
Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

BURLINGAME, Calif., February 06, 2025--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a podium presentation at the Oppenheimer 35th Annual Healthcare Life Sciences Conferenc

Business Wire last month

INVA
+0.06%
Innoviva's (NASDAQ:INVA) investors will be pleased with their 26% return over the last five years

If you buy and hold a stock for many years, you'd hope to be making a profit. But more than that, you probably want to...

Simply Wall St. 3 months ago

INVA
+0.06%
Innoviva enters distribution, license agreement with Basilea for Zevtera

Innoviva (INVA) announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica for the commercialization of Zevtera, an advanced-generation cephalosporin antibiotic, in the United States. In April, the FDA approved Zevtera for three specific treatment indications, and it is the only FDA-approved methicillin-resistant Staphylococcus aureus, or MRSA, cephalosporin antibiotic for treating adult patients with Staphylococcus aureus bloodstream infections and

TipRanks 3 months ago

INVA
+0.06%
Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

BURLINGAME, Calif., December 16, 2024--Innoviva Specialty Therapeutics, Inc., ("IST") a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution and license agreement with Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), for the commercialization of Zevtera® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the United States.

Business Wire 3 months ago

INVA
+0.06%
Innoviva to Participate in the Citi 2024 Global Healthcare Conference

BURLINGAME, Calif., November 26, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Citi 2024 Global Healthcare Conference in Miami, FL on Thursday,

Business Wire 4 months ago

INVA
+0.06%
Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that data on its critical-care, anti-infective product, eravacycline (XERAVA®), was recently presented in Los Angeles, California at IDWeek 2024. Among the findings, two in vitro study results further demonstrated the broad and consistent antimicrobial activity of eravacycline.

PR Newswire 4 months ago

INVA
+0.06%
1952.HK
Innoviva to Participate in the UBS Global Healthcare Conference

BURLINGAME, Calif., November 12, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA on Wednesday, November 13, 2024 at

Business Wire 4 months ago

INVA
+0.06%
Innoviva Third Quarter 2024 Earnings: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

Innoviva ( NASDAQ:INVA ) Third Quarter 2024 Results Key Financial Results Revenue: US$89.5m (up 33% from 3Q 2023). Net...

Simply Wall St. 4 months ago

INVA
+0.06%
Innoviva: Q3 Earnings Snapshot

BURLINGAME, Calif. AP) — Innoviva Inc. INVA) on Wednesday reported earnings of $1.2 million in its third quarter.

Associated Press Finance 4 months ago

INVA
+0.06%
Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif., November 06, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2024, and highlighted select corporate achievements.

Business Wire 4 months ago

INVA
+0.06%
Innoviva, Inc.'s (NASDAQ:INVA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Most readers would already be aware that Innoviva's (NASDAQ:INVA) stock increased significantly by 17% over the past...

Simply Wall St. 6 months ago

INVA
+0.06%
Innoviva to Participate in Upcoming Investor Conferences

BURLINGAME, Calif., September 04, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September:

Business Wire 6 months ago

INVA
+0.06%
Innoviva: Q2 Earnings Snapshot

BURLINGAME, Calif. AP) — Innoviva Inc. INVA) on Wednesday reported a loss of $34.7 million in its second quarter.

Associated Press Finance 7 months ago

INVA
+0.06%

Performance Overview

Return	INVA	S&P 500 (^GSPC)
YTD	+4.21%	-8.25%
1-Year	+22.08%	+3.55%
3-Year	-8.41%	+18.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Innoviva, Inc. (INVA)

Victoria’s Secret, Bitdeer, and More Stocks See Activist Action

WEX, Lamb Weston, and More Stocks See Action From Activist Investors

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Innoviva Full Year 2024 Earnings: EPS: US$0.37 (vs US$2.75 in FY 2023)

Innoviva: Q4 Earnings Snapshot

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Innoviva's (NASDAQ:INVA) investors will be pleased with their 26% return over the last five years

Innoviva enters distribution, license agreement with Basilea for Zevtera

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity

Innoviva to Participate in the UBS Global Healthcare Conference

Innoviva Third Quarter 2024 Earnings: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

Innoviva: Q3 Earnings Snapshot

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva, Inc.'s (NASDAQ:INVA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Innoviva to Participate in Upcoming Investor Conferences

Innoviva: Q2 Earnings Snapshot

Performance Overview